The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia

References

• Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006;99:1-14
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   Google Scholar
• Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 2006;20:205-17
   PubMed Web of Science ®Google Scholar
• Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol 2010;8:820-30
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-29
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Berthold HK, et al. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010;31:1633-9
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-13
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008;24:685-94
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Gaw A, Packard CJ, Murray EF, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13:170-89
   PubMedGoogle Scholar
• Homma Y, Ozawa H, Kobayashi T, et al. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995;114:223-34
   PubMed Web of Science ®Google Scholar
• van Tits LJ, Smilde TJ, van Wissen S, et al. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 2004;52:177-84
   PubMed Web of Science ®Google Scholar
• Lagrost L, Athias A, Lemort N, et al. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis 1999;143:415-25
   PubMed Web of Science ®Google Scholar
• van den Akker JM, Bredie SJ, Diepenveen SH, et al. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238-44
   PubMed Web of Science ®Google Scholar
• Miller M, Dobs A, Yuan Z, et al. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin 2006;22:343-50
   PubMed Web of Science ®Google Scholar
• Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956-60
   PubMed Web of Science ®Google Scholar
• Bahadir MA, Oguz A, Uzunlulu M, et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 2009;16:684-90
   PubMed Web of Science ®Google Scholar
• Zhang B, Miura S, Yanagi D, et al. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis 2008;201:353-9
   PubMed Web of Science ®Google Scholar
• Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801
   PubMed Web of Science ®Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO, et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419-32
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009;25:2571-6
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
   PubMed Web of Science ®Google Scholar
• Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
   PubMed Web of Science ®Google Scholar
• Stojakovic T, de Campo A, Scharnagl H, et al. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest 40:187-94
   PubMed Web of Science ®Google Scholar
• Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 2006;55:599-604
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Saougos V, et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pre-treatment. Arch Med Sci 2007; 3, 4: 344-50
   Web of Science ®Google Scholar
• Watson TD, Caslake MJ, Freeman DJ, et al. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb 1994;14:902-10
   PubMedGoogle Scholar
• Chung M, Lichtenstein AH, Ip S, et al. Comparability of methods for LDL subfraction determination: A systematic review. Atherosclerosis 2009;205:342-8
   PubMed Web of Science ®Google Scholar
• Apostolou F, Gazi IF, Lagos K, et al. Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes. Atherosclerosis 2010;212:607-13
   PubMed Web of Science ®Google Scholar
• Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 2006;41:647-54
   PubMed Web of Science ®Google Scholar
• Apostolou F, Gazi IF, Kostoula A, et al. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res 2009;50:2532-9
   PubMed Web of Science ®Google Scholar
• Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008;299:1678-89
   PubMed Web of Science ®Google Scholar
• Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205
   PubMed Web of Science ®Google Scholar
• Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
   PubMed Web of Science ®Google Scholar
• Blumenthal RS, Michos ED. The HALTS trial-halting atherosclerosis or halted too early? N Engl J Med 2009;361:2178-80
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010;633:62-70
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Liberopoulos EN, Achimastos A, et al. Statins: another class of antihypertensive agents? J Hum Hypertens 2006;20:320-35
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
   PubMed Web of Science ®Google Scholar